I think those warnings are for the overly cautious. Certainly we have never waited for all jobs to exit before upgrading. Out of paranoia we pause all our jobs, but that is not required. Typically you can upgrade between versions without pausing or canceling jobs. That said you will want to look at the release notes and changelog for the version you want to upgrade to in case there is any issue that is flagged that requires more paranoia. Generally minor version upgrades are fine.
The thing I would note though is this phrase "Any jobs started before the slurmd system was upgraded will be running with the old version of slurmstepd, so starting another upgrade or trying to use new features in the new version may cause problems." What really this is noting is that upgrading in quick succession (especially major upgrades) could be problematic. So say you were to go from 22.05.3 -> 23.11 and then immediately go to 25.05, that could cause problems. If you intend to go from your current version to the latest I recommend spacing out the upgrades, or taking a full downtime.
That said I have never done an upgrade over that large a version change so some one with more experience on the list should be able to answer any questions related to that. My gut says though that if I were trying to step to the latest version I would either clear out the existing jobs, or I would do one upgrade per week to give the jobs on the cluster time to adjust to the new version.
-Paul Edmon-
Out of interest, what happens if you’ve added some custom indexes to your slurmdbd? I’ve had slow query log running on ours, and added some custom indexes for certain cases, which has made sacct quite a lot faster for certain queries, but I worry about whether I’ve created a land-mine for future upgrades which include schema changes…. I can always delete the indexes as part of my SOP of course, and re-create them afterwards
Tim
AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.
This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com